| Patient’s characterisics | | |
| Age (years) | | |
| Median (IQR) | 44.0 (34.0 ; 59.0) | 29.0 (19.0 ; 43.0) |
| <18 | 4/50 (8.0) | 13/67 (19.4) |
| 18–64 | 37/50 (74.0) | 45/67 (67.2) |
| ≥65 | 9/50 (18.0) | 9/67 (13.4) |
| Female gender | 29/50 (45.3) | 35/67 (54.7) |
| Comorbidities | | |
| Respiratory disease | 3/50 (6.0) | 3/67 (4.5) |
| Interstitial lung disease | 0 | 0 |
| COPD | 1/50 (2.0) | 1/67 (1.5) |
| Asthma | 2/50 (4.0) | 2/67 (3.0) |
| Cardiovascular disease | 6/50 (12.0) | 5/67 (7.5) |
| Coronary heart diseases | 4/50 (8.0) | 5/67 (7.5) |
| Stroke | 4/50 (8.0) | 1/67 (1.5) |
| Diabetes | 5/50 (10.0) | 3/67 (4.5) |
| BMI (kg/m²) | 25.0 (21.0 ; 28.0) | 22.0 (20.0 ; 25.5) |
| <30 | 38/47 (80.9) | 60/64 (93.8) |
| 30–39.9 | 6/47 (12.8) | 4/64 (6.3) |
| ≥40 | 3/47 (6.4) | 0/64 (0.0) |
| Hypertension | 6/50 (12.0) | 6/67 (9.0) |
| Cancer | 2/50 (4.0) | 1/67 (1.5) |
| Smoking | 6/50 (12.0) | 2/67 (3.0) |
| Chronic renal failure | 2/50 (4.0) | 3/67 (4.5) |
| Number comorbidities, median (IQR) | | |
| 0 | 25/50 (50.0) | 51/67 (76.1) |
| 1 | 16/50 (32.0) | 10/67 (14.9) |
| 2 | 5/50 (10.0) | 3/67 (4.5) |
| 3 | 3/50 (6.0) | 1/67 (1.5) |
| 4 | 1/50 (2.0) | 2/67 (3.0) |
| >4 | 0 | 0 |
| Rheumatic or inflammatory Diseases treatments | |
| Corticosteroid | 19/50 (38.0) | 1/67 (1.5) |
| Systemic corticosteroid doses≥10 mg | 6/19 (31.6) | 0/1 (0.0) |
| NSSAIDs | 1/50 (2.0) | 1/67 (1.5) |
| Colchicine | 15/50 (30.0) | 57/67 (85.1) |
| Hydroxychloroquine | 0 | 0 |
| Methotrexate | 13/50 (26.0) | 0/67 (0.0) |
| Leflunomide | 0 | 0 |
| Salazopyrine | 0 | 0 |
| Mycophenolate Mofetil / mycophenolic acid | 0 | 0 |
| Azathioprine | 4/50 (8.0) | 0/67 (0.0) |
| IgIV | 0 | 0 |
| Targeted biologic or synthetic therapies | | |
| anti-TNF | 14/50 (28.0) | 4/67 (6.0) |
| anti-IL6 | 5/50 (10.0) | 0/67 (0.0) |
| anti-IL17A | 0 | 0 |
| anti-IL1 | 4/50 (8.0) | 8/67 (11.9) |
| abatacept | 1/50 (2.0) | 0/67 (0.0) |
| JAK inhibitor | 1/50 (2.0) | 0/67 (0.0) |
| Other biologics | 1/50 (2.0) | 0/67 (0.0) |
| Severity of COVID-19 Infection | | |
| Mild | 35/50 (70.0) | 55/67 (82.1) |
| Moderate | 9/50 (18.0) | 8/67 (11.9) |
| Severe | 6/50 (12.0) | 4/67 (6.0) |
| Length of hospital stay (days), median (IQR) | 12 (6 to NA) | 5 (2 to NA) |
| Death | 4/50 (8.0) | 2/67 (3.0) |